BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32122920)

  • 1. Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells.
    Scurr MJ; Greenshields-Watson A; Campbell E; Somerville MS; Chen Y; Hulin-Curtis SL; Burnell SEA; Davies JA; Davies MM; Hargest R; Phillips S; Christian AD; Ashelford KE; Andrews R; Parker AL; Stanton RJ; Gallimore A; Godkin A
    Clin Cancer Res; 2020 Jul; 26(13):3360-3370. PubMed ID: 32122920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
    Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
    J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
    Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.
    Granot T; Yamanashi Y; Meruelo D
    Mol Ther; 2014 Jan; 22(1):112-22. PubMed ID: 24025748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
    Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
    Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?
    Kayser S; Watermann I; Rentzsch C; Weinschenk T; Wallwiener D; Gückel B
    J Cancer Res Clin Oncol; 2003 Jul; 129(7):397-409. PubMed ID: 12836015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
    Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
    Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
    Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
    Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers.
    Zhang H; Liu L; Zhang J; Chen J; Ye J; Shukla S; Qiao J; Zhan X; Chen H; Wu CJ; Fu YX; Li B
    Clin Cancer Res; 2020 Mar; 26(6):1359-1371. PubMed ID: 31831563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogene therapy.
    Lichtor T; Glick RP
    Adv Exp Med Biol; 2012; 746():151-65. PubMed ID: 22639166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
    Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
    Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes.
    Schag K; Schmidt SM; Müller MR; Weinschenk T; Appel S; Weck MM; Grünebach F; Stevanovic S; Rammensee HG; Brossart P
    Clin Cancer Res; 2004 Jun; 10(11):3658-66. PubMed ID: 15173072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.
    Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ
    Front Immunol; 2021; 12():782448. PubMed ID: 34868059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
    Lu YC; Yao X; Crystal JS; Li YF; El-Gamil M; Gross C; Davis L; Dudley ME; Yang JC; Samuels Y; Rosenberg SA; Robbins PF
    Clin Cancer Res; 2014 Jul; 20(13):3401-10. PubMed ID: 24987109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
    Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
    Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
    Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
    Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
    de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
    Front Immunol; 2021; 12():592031. PubMed ID: 34335558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.